Nurix Therapeutics announces new clinical data from Phase 1a study NX-1607

Nurix Therapeutics (NRIX) announced the presentation of new clinical data from its first-in-human Phase 1a study of NX-1607, a first-in-class oral inhibitor of the E3 ligase Casitas B-lineage lymphoma proto-oncogene B in patients with relapsed/refractory solid tumors. The data are being presented at the European Society for Medical Oncology Congress, ESMO 2025, taking place October 17-21, 2025, in Berlin, Germany. As of the 26 July 2025 data cut, 71 patients were evaluable for response, with a disease control rate of 49.3%. With respect to duration of response, 7 patients achieved either stable disease or partial response for greater than or equal to5 months on treatment and 1 patient with MSS CRC achieved a PR and was treated for 27 months. Further supporting the dose-dependent activity of NX-1607, the greatest reductions in PSA among the prostate cancer patients were achieved in the BID dosing groups with 6/13 patients having PSA reductions of greater than or equal to50%. NX-1607 was shown to be tolerable at pharmacologically active doses and has a safety profile comparable to approved immuno-oncology agents, with most adverse events Grade 2 or less in severity.